AbbVie Inc (ABBV)
AbbVie Inc (ABBV) carries a ŷRobot AI score of 69 out of 100. The model's fair value estimate is $331.61, 12.3% above the last close of $295.17. The chart signal reads Sell.
| Metric | ABBV |
|---|---|
| AI score | 69 / 100 |
| Chart signal | Sell |
| Fair value estimate | $331.61 |
| Upside to fair value | 12.3% |
| Previous close | $295.17 |
| P/E | 50.67 |
| Price / sales | 7.65 |
| Market cap | $521.41B |
| EPS | 5.70 |
| Revenue growth | 2.0% |
| 1-year price change | 13.9% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR, AstraZeneca PLC.
Questions about ABBV
Is ABBV overvalued or undervalued right now?
As of Nov 3, 2026, ŷRobot's fair-value model estimates AbbVie Inc (ABBV) at $331.61 against a last close of $295.17, implying 12.3% upside to the model's estimate.
Is ABBV's chart signal bullish or bearish?
The chart-signal model classifies ABBV as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is ABBV's ŷRobot AI score?
ABBV scores 69 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ABBV stock expensive on P/E and P/S?
ABBV trades at 50.7 times earnings and 7.7 times sales as of Nov 13, 2026.
What does ABBV's seasonal forecast show?
ŷRobot's seasonal forecast curve for ABBV reads +1.9% at 30 days, +3.8% at 90 days, and +13.9% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ABBV growing?
AbbVie Inc's revenue growth is +2.0% and free-cash-flow growth is +13.5% on the latest reported figures.
ABBV chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.